Antibiotic susceptibility pattern of Eschrichia coli isolates from clinical specimens at PIMS, Islamabad by Khan, J et al.




ANTIBIOTIC SUSCEPTIBILITY PATTERN OF ESCHRICHIA COLI ISOLATES FROM CLINICAL SPECIMENS AT 
PIMS, ISLAMABAD 
 
Jafar Khan1,4, Irum Khalil1, Naser M. AbdEl-Salam2, Sehrish Liaqat1, Naila Younas1, Sameerah Mushtaq1, Riaz 
Ullah3 
 
1Department of Microbiology, Kohat University of Science and Technology, Kohat KPK Pakistan 
2Riyadh Community College, King Saud University, Riyadh 11437, Saudi Arabia 
3Department of Chemistry, Government College Ara Khel, FR Kohat, Khyber Pakhtunkhwa 26000, Pakistan 




Background: E. coli is the most common producer of extended spectrum beta lactamase enzyme (ESBL) which confers broad spectrum resistance to 
antibiotics like penicillin, cephalosporin and monobactum.  
Methods and Materials: The present study was carried out at Pakistan Institute of Medical Sciences, Islamabad. The marked resistance was viewed 
against amoxicilline-clavulanic acid, ceftriaxone and ceftazidime. The most effective drugs established were sulbactum-cefoparazone, amikacin, 
pepircillin-tazobactum. A total of 220 samples of wide range were selected, i.e., blood, urine, pus, sputum, etc. and were analyzed using various 
techniques of Gram staining and biochemical identification. 
Results:  After performing antibiotic sensitivity tests, 83% samples came out to be ESBL positive and 17% were ESBL negative.   
Conclusion: It was concluded that to ensure adequate treatment of infections arising especially from urinary pathogens and controlling spread of 
bacterial resistant strains, the continuous monitoring by bacterial susceptibility testing is essential. 
 





               Antibacterial resistance has become an important problem worldwide. The development of antibiotics resistance in E. coli has important 
clinical implications. Antimicrobial agents are most important in treatment of bacterial infections (Dworkin and Falkow; 2006). Urinary tract 
infection (UTI) is a common community acquired bacterial infection which frequently affects female outpatient, children and is one of the main 
causes of nosocomial infections in humans. It has also been stated that these opportunistic pathogens are responsible for ulcerative colitis and 
hemolytic uremic syndrome (HUS) and a potentially fatal kidney disease (Kaper et al 2004, Rolhion and arfeuille; 2007). E. coli accounts for 75-90% 
of all UTI’s in both the in patients as well as outpatients of the hospitals. Specific risk factors that lead to the spread of ESBL producing organism 
include prolonged hospitalization, severity of illness, incubation and urinary arterial catheterization, low body weight and previous exposure to broad 
spectrum of antibiotics (Lin et al; 2003, Tumbarello et al; 2007).  
             The first isolation of ESBL production by E. coli strain was done in 1987; a number of outbreaks caused by these organisms have been 
reported worldwide. Multiple drug resistance has significantly increased in recent years. The existences of extended-spectrum beta lactamase 
producing organisms are resistant to virtually all beta lactam antibiotics (Karlowsky et al., 2002). The increase in drug resistance in these organisms 




Materials and Methods 
 
This study was carried out at Pakistan Institute of Medical Sciences (PIMS) Islamabad and a total of 220 E. coli isolates were collected 
from different wards of the hospital. Different specimen like blood, sputum, urine, pus, wound, etc. were screened for the infection. The specimen 
was inoculated into blood agar, MacCkonkey agar and CLED agar. The E.coli was also cultivated on glucose and other carbohydrates containing 









Indole test was carried out to check the presence of tryptophanase enzyme to which E. coli is positive. Organisms that can use citrate as 
their sole source of carbon can turn the color of Simon’s Citrate agar from green to blue which is tested by Citrate utilization test. It differentiates 
between Enterobacteriacea from other Gram negative organisms. Motility test was done by stabbing deep a loop full of organism into the nutrient 




agar which differentiates the bacteria as motile or non-motile. Testing for urease enzyme activity was done to identify enterobacteria from other non-
urease producers. It was done by inoculating the test organism into urease agar. TSI test was carried out to check the ability of the test organism to 
ferment different sugars. A wire loop loaded with test organism was inoculated onto the TSI agar slants and results were noted after 24 hours of 
incubation. 
 
API 20E Analysis 
 
The purpose of using the API 20E was for the micro standard system of specific identification of E. coli from the rest of the fastidious 
Gram negative rods. It contains a strip with 20 microtubules containing dehydrated substrates, inoculated with the bacterial suspension (Philipon et 
al. 1989).  The previously isolated known colonies of E. coli were subjected to analysis as control. By using a sterile syringe, all wells of strip were 
filled according to the instructions of API20E manual. An anaerobic environment was created in ADH, LCD, ODH, H2S, UREA tubules by putting a 
drop of mineral oil overlay. Incubation box was closed and placed in incubator at 37C for 24 hours. 
 
Antibiotic Sensitivity Tests 
 
Kirby-Bauer disk diffusion technique was used for antimicrobial susceptibility testing (Lin et al; 2003, Tumbarello et al; 2007). The dried 
surface of a Mueller-Hinton agar plate was inoculated by streaking the swab over the entire surface in order to make lawns. Antibiotic disks were 





The present study was conducted on various clinical isolates from indoor and outdoor patients to determine the prevalence of 
clinically significant E coli at Pakistan Institute of Medical Sciences (PIMS), Islamabad. Two hundred twenty samples of E. coli were 






Figure 1: Distribution of Isolates on the basis of ESBL production. 
 
Table 1: Age and gender wise distribution of isolates 
Groups Age No. of Samples 
No. of affected 
Females 
% of affected 
Females 





A 1-10 18 03 10% 15 12.5% 
B 11-20 30 09 10% 21 10.5% 
C 21-30 54 18 9.5% 36 6% 
D 31-40 42 19 6% 23 6.5% 
E 41-50 25 06 4.5% 19 7% 
F 51-60 25 15 2.5% 10 5.5% 
G 61-70 14 05 3.5% 09 2.5% 
H 71-80 12 05 2% 07 1.5% 
Total  220 80 48% 140 52% 




        
Cultural Characteristics of Isolates 
 
Isolates were cultivated on blood agar, MacCkonkey agar and CLED agar. Following were the results after 24 hours of 
incubation period. 
Table 2: Culturing results of obtained isolates: 
Media Incubation time Colony Color Colony Shape 
Blood agar 24  hours Grey Round and moist 
MacCkonkey agar 24 hours Dark Pink Pinpointed 
CLED agar 24 hours Yellow Round 
 
                              
 












For biochemical characterization, a series of biochemical analyses for E. coli were performed such as citrate utilization, TSI, VP, indole, 
oxidase, urease and motility tests. 
 
Table 3: Biochemical test results for E. coli 
 
Biochemical Test Observation Result 
Indole Red ring appeared + 
Voges-Poskeur Yellowish brown color appeared - 
Citrate utilization No color change of media - 
Oxidase No color appearance - 
Motility Streaks along the stab were seen + 
Urease Orange color appeared - 
TSI Yellow color of medium + gas 
production 
Fermentation and gas production 
 






                     
 
Figure 4: Indole, VP, Citrate utilization and TSI tests 
 
      
 
Figure 5: Oxidase, Urease and Motility tests 
 
Results on API 20E System 
 
API 20E is a micro standardized identification system for enterobacteriacea. After biochemical identification of E. coli they 
were confirmed with API 20E. The results were taken on analysis slips by comparing with the reading table. The generated number for 
E. coli was 8101, which was same as per API 20E manual. The results for E. coli on API 20 E system were in conformity with the 












Antibiotic Susceptibility Analysis 
 
 Antibiotic sensitivity was checked for all E. coli isolates and 83% were found to be ESBL positive. The department and ward 














Amoxicillin 47 (94%) 3(9%) 0 (0.0%) 50 (100%) 
Ceftazidime 45 (90%) 6 (5%) 0 (0.0%) 50 (100%) 
Ceftriaxone 44 (88%) 6 (12%) 0 (0.0%) 50 (100%) 
Tazobactum 19 (38%) 29 (58%) 2 (4%) 50 (100%) 
Sulbactum-
cefparazone 
8 (16%) 41 (82%) 1 (2%) 50 (100%) 
Amikacin 14 (28%) 30 (60%) 1 (2%) 45 (90%) 
Imipenem 13 (24%) 28 (56%) 0 (0.0%) 40 (80%) 
Polymyxin B 14 (28%) 26 (52%) 0 (0.0%) 40 (80%) 
Tobramycin 24 (48%) 20 (40%) 0 (0.0%) 44 (88%) 
Piperacilline 15 (30%) 19 (38%) 1 (2%) 35 (70%) 
Levofolxacin 20 (40%) 19 (38%) 5 (10%) 44 (88%) 
Norfloxacin 5 (10%) 10 (20%) 0 (0%) 15 (30%) 
Ciprofloxacin 5 (10%) 2 (4%) 0 (0%) 7 (14%) 
 
 










Amoxicillin 47 (94%) 3(6%) 0 (0.0%) 50 (100%) 
Ceftazidime 43 (86%) 7 (17%) 0 (0.0%) 50 (100%) 
Ceftrixone 45 (90%) 5 (10%) 0 (0.0%) 50 (100%) 
Tazobactum 18 (36%) 32 (64%) 4 (0.0%) 50 (100%) 
Sulbactum-cefparazone 22 (44%) 28 (56%) 0 (0.0%) 50 (100%) 
Amikacin 6 (12%) 22 (44%) 1 (2%) 30 (60%) 
Imipenem 3 (6%) 29 (58%) 3 (6%) 35 (70%) 
Polymyxin B 1 (2%) 28 (56%) 0 (0.0%) 31 (62%) 
Tobramycin 7 (14%) 17 (34%) 2 (4%) 26 (52%) 
Piperacillin 7 (14%) 5 (10%) 0 (0.0%) 12 (24%) 
Levofloxacin 8 (16%)       9 (18%) 0 (0.0%) 17 (34%) 
Norfloxacin 2 (4%) 3 (6%) 0 (0%) 5 (10%) 
Ciprofloxacin 3 (6%) 7 (14%) 1 (2%) 10 (20%) 












































































Ampicillin 42 (84%) 8 (16%) 0 (0.0%) 50 (100%) 
Ceftazidime 40 (8-%) 10 (20%) 0 (0.0%) 50 (100%) 
Ceftrixone 42 (84%) 8 (16%) 0 (0.0%) 50 (100%) 
Tazobactum 15 (30%) 34 (68%) 1 (2%) 50 (100%) 
Sulbactum-
cefparazone 
13 (26%) 35 (70%) 2 (4%) 50 (100%) 
Amikacin 20 (40%) 20 (40%) 5 (10%) 45 (90%) 
Imipenem 14 (28%) 28 (56%) 0 (0.0%) 42 (84%) 
Polymyxin B 12 (24%) 30 (60%) 0 (2%) 42 (84%) 
Tobramycin 25 (50%) 18 (36%) 2 (8%) 45 (90%) 
Piperacillin 14 (28%) 20 (40%) 4 (1%) 35(70%) 
Levfloxacin 30 (60%)       14 (28%) 2 (0.0%) 44 (88%) 
Norfloxacin 7 (14%) 10 (20%) 0 (0.0%) 17 (34%) 









Ampicillin 23 (92%) 3(12%) 0 (0.0%) 25 (100%) 
Ceftazidime 23 (92%) 2 (8%) 0 (0.0%) 25 (100%) 
Ceftriaxone 24 (96%) 1 (4%) 0 (0.0%) 25 (100%) 
Tazobactum 8 (32%) 15 (60%) 2 (8%) 25 (100%) 
Sulbactum-cefparazone 6 (24%) 19 (76%) 0 (0.0%) 25 (100%) 
Amikacin 3 (12%) 10 (40%) 0 (0.0%) 13 (52%) 
Imipenem 2 (8%) 19 (76%) 0 (0.0%) 21 (84%) 
Polymyxin B 1 (4%) 18 (72%) 0 (0.0%) 19 (76%) 
Tobramycin 8 (32%) 5 (20%) 2 (8%) 15 (60%) 
Piperacillin 5 (20%) 3 (12%) 0 (0.0%) 8 (32%) 
Levofloxacin 15 (60%)       6 (24%) 0 (0.0%) 20 (80%) 
Norfloxacin 1 (4%) 3 (12%) 0 (0%) 4 (16%) 
Ciprofloxacin 5 (20%) 6 (24%) 0 (0.0%) 11 (44%) 
  





















Ampicillin 40 (88.8%) 5 (11.1%) 0 (0.0%) 45 (100%) 
Ceftazidime 39 (86.6%) 6 (13.3%) 0 (0.0%) 45 (100%) 
Ceftrixone 41 (91%) 4 (8.8%) 0 (0.0%) 45 (100%) 
Tazobactum 7 (15.5%) 35 (77.7%) 3 (6.6%) 45 (100%) 
Sulbactum-cefparazone 10 (22.2%) 33 (73.3%) 2 (4.4%) 45 (100%) 
Amikacin 4 (8.8%) 28 (62.2%) 0 (0.0%) 32 (71.1%) 
Imipenem 3 (6.6%) 27 (60%) 1 (02.2%) 31 (68.8%) 
Polymyxin  3 (6.6%) 29 (64.4%) 0 (0.0%) 32 (71.1%) 
Tobramycin 11 (24%) 13 (28.8%) 0 (0.0%) 24 (53.3%) 
Piperacillin 5 (11.1%) 2 (4.4%) 0 (0.0%) 7 (15.5%) 
Levofloxacin    19 (42.2)       7 (15.5%) 1 (2.2%) 27 (60%) 
Norfloxacin 4 (8.8%) 4 (8.8%) 0 (0.0%) 8 (17.7%) 





A number of studies have reported the prevalence of ESBL producing organisms, particularly E. coli isolates. It was found in this study that 
male and female patients were near equally infected, i.e., with the percentage value of 52% and 48% respectively. Growth rate was found to be higher 
in patients of 1-10 years of age as compared to other groups as also observed in a likewise study (Kamberovik et al; 2006). ESBL production was 
determined for all the 220 E. coli isolates and only 17.%  were found  negative ESBL  as  similarly  observed in another setting (Chaikittisuk et a;l 
2007).  E. coli the most prevalent Gram negative bacilli from clinical samples of pus, blood, urine etc were found predominant as also observed in 
cases similar where E. coli was seen widely distributed in environment and cause a variety of infections in community and hospitalized settings 
(Donnenberg et al; 2005). The prevalence of infected males was slightly higher than infected females.  Noticeable resistance was found among the 
isolates against one of the class of beta lactam antibiotics. These results are comparable to related outcomes in a study. (Philippon and Arlet; 2006). 
The marked resistance of E. coli was viewed against penicillin group like that of amoxicilline-clavulanic acid as seen also in another study (Zehra et 
al 2011).  
The most effective drugs established in this setting were sulbactum-cefoparazone, amikacin and papircilline-tazobactum. Almost all the 
isolates were sensitive to imipenem which is as likewise reported (Patrícia et al., 2010).  In conclusion, a relatively high antibiotic resistance was 
observed among the isolated E. coli strain and no doubt that growing problem of antimicrobial resistance has become a growing public health 
concern, especially in developing countries. This phenomenal increase in drug resistance is greatly contributed to by the misuse of antibiotics that 
have led to the prevailing alarming situation (Marwa et al; 2012, Ruifang et al; 2006, Rahbar et al; 2007). Selection of drug of choice in any 
condition especially in chronic diseases is not easy. In case of infectious diseases, we have to pay attention to microbial sensitivity and 
resistance pattern observation for various antimicrobials (Asti; 2013). Moreover, monitoring ESBL production and antimicrobial susceptibility 
testing are necessary to reduce the burden of increasingly resistant pathogens (Mohanalakshmi et al; 2014). Therefore, the antibiotic stewardship 
guidelines need to be   recommended and strictly adopted in a comprehensive control program to reduce the high levels of bacterial antibiotic 
resistance (Gautam et al; 2013). In the perspective of this study, the patients’ sufferings with proper public health plans can be minimized with a 





It was concluded that to ensure adequate treatment of infections arising especially from urinary pathogens and controlling spread of 
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